bluebird bio Announces Transition of Chief Financial Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
BlueBird Bio (BLUE) Post Quarter Update: Starbeam Trial Interim at AAN Next - Leerink
February 29, 2016 7:07 AM ESTLeerink Partners analyst, Jonathan Chang sees bluebird bio (NASDAQ: BLUE) gene therapy LentiGlobin as the key value driver for the stock with initial clinical proof-of-concept (POC) achieved in hemoglobinopathies and next clinical updates expected at the ASH annual meeting in Dec. Near term, positive Lenti-D interim Ph II/III data in ultra-rare Childhood Cerebral Adrenoleukodystrophy (CCALD) at the American Academy of Neurology (AAN) annual meeting (April 15-21) could represent important platform validation.
CCALD is a rare severe and progressive central nervous system (CNS) disease. While... More
